Historical Signal Evaluation: Metamizole and Agranulocytosis

Purpose and Scope

Metamizole is an analgesic and antipyretic authorised in a number of European countries for indications that vary nationally. Agranulocytosis—a severe reduction in circulating granulocytes that can lead to life-threatening infection—has long been recognised as an adverse reaction to metamizole.

The 2024 EU procedure is therefore not best understood as discovery of a new signal. It is a case study in reassessment of a known risk and the effectiveness of existing risk minimisation.

Finland requested an urgent Union procedure after agranulocytosis cases continued to be reported despite strengthened national risk-minimisation measures. PRAC reviewed the totality of evidence and concluded that the benefit-risk balance remained favourable but that risk communication and clinical instructions should be strengthened. CMDh endorsed the measures, and the European Commission issued the final decision on 22 November 2024.

This sequence illustrates an important pharmacovigilance principle: an established adverse reaction can still generate a new regulatory question when its seriousness, clinical management, susceptible populations or existing control measures require reassessment.

The Clinical Risk

Granulocytes, particularly neutrophils, are white blood cells central to defence against bacterial and fungal infection. Agranulocytosis describes a profound granulocyte deficiency. The clinical danger arises not simply from an abnormal laboratory value but from loss of a major component of innate immune defence.

Early manifestations can include fever, chills, sore throat and painful mucosal lesions. These symptoms are not specific, which creates a detection problem: metamizole may itself be used to treat fever, and concomitant antibiotics can mask manifestations of infection. Delayed recognition can therefore allow severe infection to develop before the blood abnormality is identified.

The 2024 review emphasised that metamizole-induced agranulocytosis can occur at any time during treatment or shortly after discontinuation, including in patients who previously used the medicine without complication. EMA also states that the reaction is not dose-dependent.

These characteristics matter for risk minimisation. A strategy based only on cumulative dose or on reassurance from prior uneventful treatment would not adequately address the known risk.

Why the 2024 Review Was Triggered

Under Article 107i of Directive 2001/83/EC, an urgent Union procedure can be initiated when a safety issue may require significant regulatory action. The Finnish medicines authority initiated the metamizole procedure in June 2024 after cases continued to occur despite recent strengthening of national measures, and after the company marketing the only metamizole-containing medicine authorised in Finland requested withdrawal of its marketing authorisation for safety reasons.

The regulatory question was therefore broader than whether metamizole can cause agranulocytosis. That relationship was already known. PRAC needed to determine whether the available evidence altered the benefit-risk balance and whether existing measures were sufficient to minimise serious outcomes across the EU.

This distinction should shape the evidence review: when a risk is established, the evaluation must focus not only on causality but also on preventability, early recognition, susceptible populations and the effectiveness of existing controls.

Evidence Considered by PRAC

The public regulatory record shows that PRAC reviewed evidence submitted by marketing authorisation holders, EudraVigilance data, scientific literature, stakeholder submissions and advice from an ad-hoc expert group. This breadth is important because no single source can answer every question about a rare, serious idiosyncratic reaction.

Spontaneous reports help describe clinical presentation, timing and serious outcomes. Literature can contribute epidemiology and mechanistic understanding. Expert review can clarify the clinical feasibility of proposed risk-minimisation measures. The regulatory assessment integrates these streams rather than treating one database or one incidence estimate as determinative.

The 2024 review concluded that agranulocytosis can occur at any time during treatment or shortly afterwards and is not dose-dependent. These conclusions directly affect prevention strategy: neither limiting cumulative exposure nor relying on prior tolerance can reliably identify all patients at risk.

Why Routine Blood-Count Monitoring Was Reconsidered

One of the most instructive outcomes was PRAC's conclusion that the review did not identify evidence supporting the effectiveness of routine regular blood-count monitoring for reducing serious outcomes of metamizole-induced agranulocytosis. The revised approach instead emphasised symptom recognition, immediate treatment interruption and prompt blood testing when agranulocytosis is suspected.

This is a useful example of evidence-based risk minimisation. A control can appear intuitively protective without being demonstrated to work effectively for the event's clinical behaviour. Because metamizole-induced agranulocytosis can develop abruptly and unpredictably, periodic testing may not provide timely warning in every case.

The regulatory conclusion should not be generalised beyond this specific risk. It does not mean routine laboratory monitoring is ineffective for other adverse reactions. It means that, for this particular reaction and evidence base, PRAC did not identify support for the existing routine-monitoring recommendation as an effective early-detection strategy.

Strengthened Risk-Minimisation Measures

PRAC recommended stronger and clearer instructions to patients and healthcare professionals. Patients should be informed about symptoms such as fever, chills, sore throat and painful mucosal lesions and instructed to stop metamizole and seek urgent medical attention if these occur. When agranulocytosis is suspected, a blood count including differential white-cell count should be performed immediately and treatment discontinued while results are awaited.

The review also strengthened contraindications for patients with previous metamizole-induced agranulocytosis or agranulocytosis caused by related pyrazolones or pyrazolidines, as well as patients with impaired bone-marrow function or diseases affecting haematopoiesis.

These measures reflect the causal model established by the review: risk is idiosyncratic and not dose-dependent, prior uneventful use does not eliminate susceptibility, early symptoms may be masked, and prompt recognition and drug withdrawal are central to preventing serious complications.

Benefit-Risk Reasoning

Despite the seriousness of agranulocytosis, PRAC concluded that the benefits of metamizole-containing medicines continued to outweigh their risks under strengthened conditions of use. This illustrates why regulatory pharmacovigilance does not equate recognition of a serious adverse reaction with automatic withdrawal.

Benefit-risk assessment considers the medicine's therapeutic role, the severity and preventability of the risk, available alternatives, the feasibility of risk minimisation and the consequences of different regulatory options. In 2024, the EU response was harmonised strengthening of risk communication and clinical management rather than EU-wide suspension.

A Known Risk Can Generate New Safety Action

Signal-management terminology is sometimes used too narrowly, as though pharmacovigilance activity ends once an adverse reaction is listed. The metamizole case demonstrates the opposite. New evidence about clinical presentation, preventability or effectiveness of existing measures can require renewed assessment of a known risk.

For an MAH, the operational question is therefore not simply whether agranulocytosis is already in the reference safety information. It is whether new cases or external regulatory evidence reveal a material change in understanding or show that current controls may not be sufficiently effective.

Failure Modes in Evaluation and Implementation

One failure mode would be to describe the 2024 procedure as discovery of an unknown adverse reaction. Agranulocytosis was already established; the new regulatory problem concerned the adequacy and harmonisation of risk minimisation.

A second error would be to preserve a familiar control simply because it appears prudent. The routine blood-count recommendation demonstrates why controls themselves require evidence of effectiveness. When a measure does not fit the clinical behaviour of the risk, retaining it can create false reassurance or divert attention from more useful action.

Other potential failure modes include incomplete capture of symptom timing, failure to consider masking by antipyretic use or antibiotics, inability to identify previous pyrazolone-associated agranulocytosis, delay in implementing harmonised product-information changes, and failure to communicate the revised clinical response clearly. These are illustrative failure modes, not claims about findings at any particular company.

Inspection and Governance Considerations

For an MAH affected by the procedure, an inspector could reasonably ask how the European Commission decision was identified, assessed and translated into local product information; whether relevant SOPs, educational or medical-information content were updated where necessary; how implementation across affiliates and partners was tracked; and whether subsequent cases are assessed against the revised understanding of timing, susceptibility and masking factors.

Governance should also show that the organisation can distinguish a known risk from new information about that risk. A serious case may not constitute a new signal, but a recurring pattern of delayed recognition, an unexpected susceptible subgroup or evidence that a risk-minimisation measure is ineffective could still require escalation.

The QPPV should have appropriate visibility of significant regulatory safety action and its implementation across the pharmacovigilance system. This does not create a universal requirement for personal QPPV approval of every local implementation document.

Summary

The 2024 EU metamizole review is a strong teaching case because causality was not the central unresolved question. Metamizole-induced agranulocytosis was already known. The procedure examined whether continuing cases and experience with existing controls required a different approach to minimising serious outcomes.

PRAC concluded that the reaction is not dose-dependent, can occur during treatment or shortly after discontinuation, and may occur despite previous uneventful use. The review found no evidence supporting routine blood-count monitoring as an effective early-detection strategy and instead strengthened symptom-based recognition, immediate interruption and prompt differential blood testing when agranulocytosis is suspected. CMDh endorsed the recommendations and the European Commission issued the final decision on 22 November 2024.

The broader pharmacovigilance lesson is that risk management is itself evidence based. A known adverse reaction remains a live PV issue when new evidence changes how the risk should be recognised, communicated or controlled.

References

1. European Medicines Agency. Metamizole-containing medicinal products — Article 107i referral. Procedure EMEA/H/A-107i/1537; 2024.
2. European Medicines Agency. EMA recommends measures to minimise serious outcomes of known side effect with painkiller metamizole. 6 September 2024.
3. European Medicines Agency. PRAC assessment report: metamizole-containing medicinal products, EMA/470471/2024. 2024.
4. European Medicines Agency. Minutes of the PRAC meeting, 2–5 September 2024.
5. European Commission. Final decision on metamizole-containing medicinal products following Article 107i procedure, 22 November 2024.
6. Directive 2001/83/EC of the European Parliament and of the Council, Article 107i.
7. European Medicines Agency. Good pharmacovigilance practices, Module V — Risk management systems; Module IX — Signal management; Module XVI — Risk minimisation measures.

Regulatory Note

The EU Article 107i procedure reached a European Commission final decision on 22 November 2024. Current national product information should be checked to confirm implementation for the specific metamizole-containing medicine. The article distinguishes the legally effective regulatory outcome from broader operational recommendations and does not create additional monitoring requirements beyond the applicable authorised information.